Related references
Note: Only part of the references are listed.Tamoxifen and oxidative stress: an overlooked connection
Nermin S. Ahmed et al.
DISCOVER ONCOLOGY (2021)
Synthesis of novel flexible tamoxifen analogues to overcome CYP2D6 polymorphism and their biological evaluation on MCF-7 cell line
Nermin S. Ahmed et al.
DRUG DEVELOPMENT RESEARCH (2020)
Ridaifen-F conjugated with cell-penetrating peptides inhibits intracellular proteasome activities and induces drug-resistant cell death
Makoto Tanaka et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Design, synthesis and characterization of novel quinacrine analogs that preferentially kill cancer over non-cancer cells through the down-regulation of Bcl-2 and up-regulation of Bax and Bad
V. Raja Solomon et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Tamoxifen from Failed Contraceptive Pill to Best-Selling Breast Cancer Medicine: A Case-Study in Pharmaceutical Innovation
Viviane M. Quirke
FRONTIERS IN PHARMACOLOGY (2017)
Design and synthesis of novel tamoxifen analogues that avoid CYP2D6 metabolism
Nermin S. Ahmed et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
Design and synthesis of novel flexible ester-containing analogs of tamoxifen and their evaluation as anticancer agents
Nehal H. Elghazawy et al.
FUTURE MEDICINAL CHEMISTRY (2016)
A novel tamoxifen derivative, ridaifen-F, is a nonpeptidic small-molecule proteasome inhibitor
Makoto Hasegawa et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2014)
Prodrugs Design Based on Inter- and Intramolecular Chemical Processes
Rafik Karaman
CHEMICAL BIOLOGY & DRUG DESIGN (2013)
Tamoxifen Use in Postmenopausal Breast Cancer: CYP2D6 Matters
Hiltrud Brauch et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Tamoxifen Resistance in Breast Cancer
Minsun Chang
BIOMOLECULES & THERAPEUTICS (2012)
The hydrolytic activity of esterases in the yeast Saccharomyces cerevisiae is strain dependent
Magdalena Kwolek-Mirek et al.
CELL BIOLOGY INTERNATIONAL (2011)
Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
D. Chen et al.
CURRENT CANCER DRUG TARGETS (2011)
Tamoxifen: the drug that came in from the cold
L. Hughes-Davies et al.
BRITISH JOURNAL OF CANCER (2009)
Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen
Werner Schroth et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer
V. Craig Jordan
STEROIDS (2007)
The NCI60 human tumour cell line anticancer drug screen
Robert H. Shoemaker
NATURE REVIEWS CANCER (2006)
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment
Y Jin et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Panel of human cancer cell lines provides valuable database for drug discovery and bioinformatics
T Yamori
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2003)
Tamoxifen: A most unlikely pioneering medicine
VC Jordan
NATURE REVIEWS DRUG DISCOVERY (2003)
Structure-function relationships of the raloxifene-estrogen receptor-α complex for regulating transforming growth factor-α expression in breast cancer cells
H Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
COMPARE: a web accessible tool for investigating mechanisms of cell growth inhibition
DW Zaharevitz et al.
JOURNAL OF MOLECULAR GRAPHICS & MODELLING (2002)
Structure-activity relationships for a large diverse set of natural, synthetic, and environmental estrogens
H Fang et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2001)
Share Paper
